The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...
Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...
Dupixent looks well positioned to reach peak ... and strong clinical data in chronic obstructive pulmonary disease (COPD) will help the drug serve additional patients. While Sanofi shares profits ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations ...
The expansion of Dupixent and COPD will give hundreds of thousands of additional patients who are living with this devastating disease, the chance to potentially improve breathing and a life with ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...
Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. This expansion positions Dupixent as the first targeted therapy for COPD, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback